Tomohiro Matsuda1, Young-Joo Won2, RuRu Chun-Ju Chiang3, Jiwon Lim2, Kumiko Saika4, Keisuke Fukui5, Wen-Chung Lee3, Laura Botta6, Alice Bernasconi6, Annalisa Trama6. 1. National Cancer Registry Section, Center for Cancer Registries, Center for Cancer Control and Information Services National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. Electronic address: tomatsud@ncc.go.jp. 2. Division of Cancer Registration and Surveillance, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang-si, 10408, Republic of Korea. 3. Taiwan Cancer Registry Center, Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Rm. 506, No. 17, Xuzhou Rd., Taipei, 100, Taiwan. 4. National Cancer Registry Section, Center for Cancer Registries, Center for Cancer Control and Information Services National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. 5. Osaka Medical College, 2-7 Daigakumachi, Takatsuki, Osaka, 569-8686, Japan. 6. Research Department, Fondazione IRCSS, Istituto Nazionale dei Tumouri, Via Venezian 1, 20133, Milan, Italy.
Abstract
INTRODUCTION: Epidemiologic information on rare cancers is scarce outside of the Western countries. The project "surveillance of rare cancers in Asia" (RARECAREnet Asia) provides, for the first time, the burden of rare cancers in some Asian countries based on the latest list. OBJECTIVES: 1) to assess whether the European list of rare cancers fits the Asian setting and 2) to compare the incidences of rare cancers between Europe and Asian countries. MATERIAL AND METHODS: Population-based cancer registry data on patients diagnosed from 2011 to 2015 in Japan, Korea, and Taiwan and patients diagnosed from 2000 to 2007 in 94 European registries were analysed. The incidences for all cancers were calculated; they were then grouped into several tiers and families according to the rare cancer list, and whether cancers rare was examined. RESULTS: Rare cancer counts according to the list in the observed population were 196 in Japan, 203 in Korea, 198 in Taiwan, and 198 in the EU. The proportions of rare in overall incidence were 16.3% in Japan, 23.7% in Korea, 24.2% in Taiwan, and 22.2% in the EU. The numbers of newly diagnosed rare cancer cases in 2015 were 140,188 in Japan, 52,071 in Korea, and 24,147 in Taiwan. CONCLUSION: Most rare cancers in Europe were also rare in the Asian countries considered. The observed differences were due to well-known risk factors. The European definition and list of rare cancers appear to reflect well cancer incidence in East Asia.
INTRODUCTION: Epidemiologic information on rare cancers is scarce outside of the Western countries. The project "surveillance of rare cancers in Asia" (RARECAREnet Asia) provides, for the first time, the burden of rare cancers in some Asian countries based on the latest list. OBJECTIVES: 1) to assess whether the European list of rare cancers fits the Asian setting and 2) to compare the incidences of rare cancers between Europe and Asian countries. MATERIAL AND METHODS: Population-based cancer registry data on patients diagnosed from 2011 to 2015 in Japan, Korea, and Taiwan and patients diagnosed from 2000 to 2007 in 94 European registries were analysed. The incidences for all cancers were calculated; they were then grouped into several tiers and families according to the rare cancer list, and whether cancers rare was examined. RESULTS: Rare cancer counts according to the list in the observed population were 196 in Japan, 203 in Korea, 198 in Taiwan, and 198 in the EU. The proportions of rare in overall incidence were 16.3% in Japan, 23.7% in Korea, 24.2% in Taiwan, and 22.2% in the EU. The numbers of newly diagnosed rare cancer cases in 2015 were 140,188 in Japan, 52,071 in Korea, and 24,147 in Taiwan. CONCLUSION: Most rare cancers in Europe were also rare in the Asian countries considered. The observed differences were due to well-known risk factors. The European definition and list of rare cancers appear to reflect well cancer incidence in East Asia.
Authors: Silvia Stacchiotti; Anna Maria Frezza; Jean-Yves Blay; Elizabeth H Baldini; Sylvie Bonvalot; Judith V M G Bovée; Dario Callegaro; Paolo G Casali; RuRu Chun-Ju Chiang; George D Demetri; Elisabeth G Demicco; Jayesh Desai; Mikael Eriksson; Hans Gelderblom; Suzanne George; Mrinal M Gounder; Alessandro Gronchi; Abha Gupta; Rick L Haas; Andrea Hayes-Jardon; Peter Hohenberger; Kevin B Jones; Robin L Jones; Bernd Kasper; Akira Kawai; David G Kirsch; Eugene S Kleinerman; Axel Le Cesne; Jiwon Lim; María Dolores Chirlaque López; Roberta Maestro; Rafael Marcos-Gragera; Javier Martin Broto; Tomohiro Matsuda; Olivier Mir; Shreyaskumar R Patel; Chandrajit P Raut; Albiruni R A Razak; Damon R Reed; Piotr Rutkowski; Roberta G Sanfilippo; Marta Sbaraglia; Inga-Marie Schaefer; Dirk C Strauss; Kirsten Sundby Hall; William D Tap; David M Thomas; Winette T A van der Graaf; Winan J van Houdt; Otto Visser; Margaret von Mehren; Andrew J Wagner; Breelyn A Wilky; Young-Joo Won; Christopher D M Fletcher; Angelo P Dei Tos; Annalisa Trama Journal: Cancer Date: 2021-04-28 Impact factor: 6.860
Authors: Gemma A Bilkey; Richard W Trevithick; Emily P Coles; Jennifer Girschik; Kristen J Nowak Journal: BMC Cancer Date: 2021-07-08 Impact factor: 4.430